I'm trying to wrap my head around the current MCap....still north of $200 million CDN.  The only rationale for a valuation that high is based on speculation about future potential value.

Biogen's Aducanumab added billions in USD to their market cap, in excess of $10 billion based on how much their valuation climbed when they moved into Phase 3 and how much if fell when the drug failed.  

If eGFR numbers and MOCA scores fail to impress...I am assuming we are done, someone turn out the lights.  If they impress with CKD and Vascular Dimentia/Alzheimer's.....I wonder what kind of reception the market would have.  Would good MOCA scores be enough to push the valutation into the billions?